Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Thromboembolism

Study type: Observational

Funder types: Industry

Identifiers

NCT01420809

112285

Details and patient eligibility

About

This post-marketing surveillance study was designed to collect and assess the information on proper use of fondaparinux injection, such as the safety and efficacy under actual use conditions, in subjects undergoing orthopedic surgery of the lower limb at high risk of developing venous thromboembolism.

(ARIXTRA® is a trademark of the GlaxoSmithKline group of companies.)

Enrollment: 1,280 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects undergo orthopedic surgery of the lower limb at high risk of developing venous thromboembolism

Exclusion criteria

• Not applicable